INmune Bio, Inc. (INMB)
1.22
+0.01
(+0.83%)
USD |
NASDAQ |
Jun 11, 10:53
INmune Bio Debt to Equity Ratio : 0.0769 for March 31, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| March 31, 2026 | 0.0769 |
| December 31, 2025 | 0.044 |
| September 30, 2025 | 0.0426 |
| June 30, 2025 | 0.0156 |
| March 31, 2025 | 0.0117 |
| December 31, 2024 | 0.012 |
| September 30, 2024 | 0.0753 |
| June 30, 2024 | 0.1465 |
| March 31, 2024 | 0.2736 |
| December 31, 2023 | 0.2737 |
| September 30, 2023 | 0.2887 |
| June 30, 2023 | 0.3037 |
| March 31, 2023 | 0.2779 |
| December 31, 2022 | 0.2547 |
| September 30, 2022 | 0.2414 |
| June 30, 2022 | 0.2192 |
| March 31, 2022 | 0.202 |
| December 31, 2021 | 0.1899 |
| September 30, 2021 | 0.1647 |
| Date | Value |
|---|---|
| June 30, 2021 | 0.3352 |
| March 31, 2021 | 0.0022 |
| December 31, 2020 | 0.0041 |
| September 30, 2020 | 0.0038 |
| June 30, 2020 | 0.007 |
| March 31, 2020 | 0.0077 |
| December 31, 2019 | 0.0071 |
| September 30, 2019 | 0.0076 |
| June 30, 2019 | 0.0069 |
| March 31, 2019 | 0.00 |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | -2.346 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Sangamo Therapeutics, Inc. | -1.020 |
| Arrowhead Pharmaceuticals, Inc. | 2.237 |
| Oncolytics Biotech, Inc. | -0.099 |
| Sarepta Therapeutics, Inc. | 0.6888 |
| Anixa Biosciences, Inc. | 0.0128 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 25.82M |
| Total Liabilities (Quarterly) | 6.194M |
| Shareholders Equity (Quarterly) | 19.62M |
| Current Ratio | 4.236 |
| Net Debt Paydown Yield | -0.75% |